Tocqueville Asset Management L.P. bought a new position in Danaher Corporation (NYSE:DHR – Free Report) during the 2nd quarter, Holdings Channel reports. The fund bought 17,540 shares of the conglomerate’s stock, valued at approximately $12,630,000.
A number of other hedge funds also recently made changes to their positions in the company. one8zero8 LLC bought a new position in Danaher during the second quarter valued at approximately $3,257,000. Kentucky Farm Bureau Mutual Insurance Co purchased a new position in Danaher during the 2nd quarter valued at approximately $1,905,000. Addison Advisors LLC bought a new stake in Danaher in the 2nd quarter worth approximately $143,000. Mmbg Investment Advisors CO. bought a new stake in Danaher in the 2nd quarter worth approximately $4,117,000. Finally, West Family Investments Inc. purchased a new stake in shares of Danaher during the 2nd quarter worth approximately $230,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.
Danaher Price Performance
NYSE:DHR opened at $211.92 on Thursday. The firm has a market capitalization of $148.98 billion, a price-to-earnings ratio of 37.64, a PEG ratio of 2.49 and a beta of 0.78. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The business has a 50 day simple moving average of $194.30 and a 200-day simple moving average of $192.44. Danaher Corporation has a 1 year low of $160.93 and a 1 year high of $242.80.
Analysts Set New Price Targets
A number of research analysts have recently commented on the company. Wolfe Research downgraded Danaher from an “outperform” rating to a “peer perform” rating in a research report on Monday, June 1st. Weiss Ratings upgraded shares of Danaher from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, July 15th. Argus decreased their price target on shares of Danaher from $265.00 to $230.00 and set a “buy” rating on the stock in a research note on Friday, April 24th. UBS Group lowered their price objective on shares of Danaher from $270.00 to $250.00 and set a “buy” rating for the company in a research report on Wednesday, April 22nd. Finally, Wells Fargo & Company dropped their price objective on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 22nd. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, Danaher presently has an average rating of “Moderate Buy” and a consensus target price of $228.91.
View Our Latest Stock Report on DHR
Danaher Company Profile
Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.
Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.
Featured Articles
- Five stocks we like better than Danaher
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
